Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + transarterial chemoembolization
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intra-arterial
01
Overview
This combination therapy involves the programmed death-1 (PD-1) immune checkpoint inhibitor nivolumab administered in conjunction with transarterial chemoembolization (TACE). Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell mediated anti-tumor immune responses. TACE is a localized treatment for hepatocellular carcinoma that involves the delivery of chemotherapy (often via drug-eluting beads) directly to the tumor's blood supply followed by embolization to induce ischemia. The combination is being investigated to determine if the local inflammatory environment and antigen release caused by TACE can synergize with the systemic immune activation of nivolumab in patients with intermediate-stage hepatocellular carcinoma.
- Brand names
- Opdivo
- Other names
- Nivolumab plus TACENivolumab + TACE
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nivolumab + transarterial chemoembolization.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + transarterial chemoembolization.